Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Sigma Pharmaceuticals history
Sigma Pharmaceuticals company history timeline
In 1985, 2.2 million of the 8.68 million outstanding shares were sold for $129.5 million.
The company was founded in 1985 by Doctor Gary Fisher, President and CEO, and Marcia Fisher, CFO, whose goal was not only to provide a wide variety of name brand and generic ophthalmic pharmaceutical & exam supply options, but also to meet the individual needs of practitioners.
By 1986 some 1.5 million company catalogs circulated yearly.
Annual Report Cover 1986
Annual Report Cover 1987
Sigma Annual Report Cover 1988
1989: Fluka Chemie AG is acquired.
1991: Company establishes its fine chemicals division to handle bulk sales.
Bader's new role was short-lived, however, as in early 1992 he was voted off the board of directors and stripped of his chairman emeritus title.
1993: Supelco, Inc. is acquired.
Annual Report Cover 1993
Annual Report Cover 1994
Launches in 1995 and today has over 40 Pharmacy Members
Sigma Mergers with Arrow Pharmaceuticals - 1995
Annual Report Cover 1995
Sigma Acquires QDL Pharmaceuticals 1996
1997: Company purchases 75 percent interest in Riedel-de Haën.
In December 1998 the company stepped up its presence in the biotechnology sector with the $39.5 million purchase of Texas-based Genosys Biotechnologies, Inc., one of the world's leading suppliers of custom synthetic DNA products--essential components of gene research.
In spite of the company's acquisition drive, growth slowed to a trickle by 1998, when sales increased by just six percent and net income barely edged ahead, increasing by only 0.1 percent.
Annual Report Cover 1998
In March 1999 Sigma-Aldrich purchased the remaining 25 percent.
1999: The remaining 25 percent of Riedel-de Haën is acquired; major restructuring is launched, reorganizing the company into four business divisions: diagnostics, fine chemicals, laboratory products, and life sciences.
The year 1999 brought with it the Company’s first strategic plan, with Davd Harvey now at the helm as CEO, taking over for Tom Cori.
With the completion in May 2000 of the sale of B-Line Systems to Cooper Industries, Inc. for $425 million, Sigma-Aldrich could, for the first time in its history, plan for the future as a company with a single focus--supplying chemicals to the life science industries.
Annual Report Cover 2001
In 2001, Sigma-Aldrich acquired Isotec, a leader in stable isotope production whose products are used in basic research and the diagnosis of disease.
Sigma Acquires Herron Pharmaceuticals in 2003
In 2004, Ultrafine, a supplier of contract manufacturing services for drug development, and Tetrionics, a producer of high potency and cytotoxic active pharmaceutical ingredients, became a strategic piece of the Company’s portfolio.
Sigmapharm Laboratories was founded by Doctor Spiro Spireas on March 1, 2005.
Also in 2005, Sigma-Aldrich announced membership in The RNAi Consortium and joined leading institutions including MIT, Harvard, and Eli Lilly to develop and distribute genome-wide shRNA libraries globally.
In 2007, Sigma-Aldrich achieved another significant milestone by exceeding $2 billion in sales, delivering record earnings and further strengthening its leadership in the markets it serves.
In 2007, Gary and Marcia's daughter, Nichole, joined the company as Director of Operations, ensuring that Sigma Pharmaceuticals remains committed to shipping only the highest quality ophthalmic products in a timely and cost-effective manner.
Annual Report Cover 2008
2008: First GMP Inspection completed by the FDA
More recently, Sigma-Aldrich acquired ChemNavigator in 2009 to provide researchers with industry-leading chemical compound selection and procurement services.
and Sigma Celebrates 2010
Annual Report Cover 2010
2010: First Paragraph-IV Litigation initiated against Sigmapharm by Gilead Sciences, Inc., for generic Adefovir Dipivoxil Tablets equivalent to HEPSERA® Tablets
The Sigma 100 Year Project Team celebrating Sigma's Birthday on the 18th of June 2012.
2013: First Product Launch of a First-to-File Paragraph-IV product (First-and-Only generic Adefovir Dipivoxil Tablets equivalent to HEPSERA® Tablets)
Rate how well Sigma Pharmaceuticals lives up to its initial vision.
Sigma Pharmaceuticals jobs
Do you work at Sigma Pharmaceuticals?
Does Sigma Pharmaceuticals communicate its history to new hires?
Sigma Pharmaceuticals history FAQs
Zippia gives an in-depth look into the details of Sigma Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Sigma Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Sigma Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Sigma Pharmaceuticals. The data presented on this page does not represent the view of Sigma Pharmaceuticals and its employees or that of Zippia.
Sigma Pharmaceuticals may also be known as or be related to Sigma Pharmaceuticals, Sigma Pharmaceuticals LLC, Sigma Pharmaceuticals Ltd and Sigma Pharmaceuticals, LLC.